These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 1797154)

  • 21. [PAF-antagonists with a phospholipid structure. 5. Propanediol phospholipids with various substituted pyridinium and quinuclidinium head groups and variations of the phosphorus-nitrogen distance;synthesis, characterization and structure activity relationship].
    Kertscher HP; Schwabe W; Grupe R
    Pharmazie; 1993 Jan; 48(1):23-6. PubMed ID: 8460172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the synthetic ether phospholipid KO-286011 on cells and components of rabbit blood.
    Hofmann B; Greiner J; Glusa E; Kertscher HP; Ostermann G
    Haemostasis; 1991; 21(2):77-84. PubMed ID: 1959801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of platelet-activating factor in long-term potentiation of the rat medial vestibular nuclei.
    Grassi S; Francescangeli E; Goracci G; Pettorossi VE
    J Neurophysiol; 1998 Jun; 79(6):3266-71. PubMed ID: 9636125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
    Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
    J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet aggregation induced by ether-linked phospholipids. 2. Mechanism of desensitization of rabbit platelets by platelet activating factor and reversibility of inhibitory actions of its antagonists.
    Tokumura A; Yoshida J; Okasaka N; Fukuzawa K; Tsukatani H
    Thromb Res; 1987 Apr; 46(1):153-61. PubMed ID: 3590110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of the platelet-activating factor antagonist, BN 52021, on human natural killer cell-mediated cytotoxicity.
    Mandi Y; Farkas G; Koltai M; Beladi I; Mencia-Huerta JM; Braquet P
    Immunology; 1989 Jul; 67(3):370-4. PubMed ID: 2759659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of platelet activating factor antagonists on the protamine sulphate stimulated release of histamine from peritoneal mast cells of rats in vitro.
    Lohde C; Bahr T; Labes D; Grupe R
    Arzneimittelforschung; 1992 Jan; 42(1):27-31. PubMed ID: 1375025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Action of platelet-activating factor (PAF) antagonists on the bronchopulmonary effects of PAF in the guinea-pig.
    Pons F; Touvay C; Lejeune V; Carré C; Vilain B; Broquet C; Mencia-Huerta JM; Braquet P
    J Lipid Mediat; 1989; 1(6):329-40. PubMed ID: 2519901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
    Terashita Z; Imura Y; Takatani M; Tsushima S; Nishikawa K
    J Pharmacol Exp Ther; 1987 Jul; 242(1):263-8. PubMed ID: 3612533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective inhibition of adrenaline-induced human platelet aggregation by the structurally related Paf antagonist Ro 19-3704.
    Schattner M; Parini A; Fouque F; Vargaftig BB; Touqui L
    Br J Pharmacol; 1989 Apr; 96(4):759-66. PubMed ID: 2787179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet activating factor antagonists: synthesis and structure-activity studies of novel PAF analogues modified in the phosphorylcholine moiety.
    Takatani M; Yoshioka Y; Tasaka A; Terashita Z; Imura Y; Nishikawa K; Tsushima S
    J Med Chem; 1989 Jan; 32(1):56-64. PubMed ID: 2909744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histamine potentiates human platelet aggregation induced by platelet-activating factor.
    Sipka S; Koltai M; Braquet P; Szegedi G
    Int Arch Allergy Immunol; 1992; 97(1):89-92. PubMed ID: 1582704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-activity relationships in platelet-activating factor (PAF). 5. Synthesis and in vitro antagonistic activities of ketophosphonates.
    Furno-de Winter A; Broquet C; Haelters JP; Massicot F; Sturtz G; Godfroid JJ
    J Lipid Mediat; 1991; 3(3):289-300. PubMed ID: 1773030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BN 52021 displaces [3H]paf-acether from, and inhibits its binding to intact human platelets.
    Korth R; Benveniste J
    Eur J Pharmacol; 1987 Oct; 142(3):331-41. PubMed ID: 3428349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists.
    Vogensen SB; Strømgaard K; Shindou H; Jaracz S; Suehiro M; Ishii S; Shimizu T; Nakanishi K
    J Med Chem; 2003 Feb; 46(4):601-8. PubMed ID: 12570381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [PAF-antagonists with lipid structure. 6. Alkylpropandiol lipids with acyl- and ether- structures at the C-3 position and heterocyclic head groups; synthesis, characterization and structure-activity relationship].
    Kertscher HP
    Pharmazie; 1997 Sep; 52(9):672-5. PubMed ID: 9411454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of guinea pig peritoneal macrophages by platelet activating factor (PAF) and its agonists.
    Hayashi H; Kudo I; Inoue K; Onozaki K; Tsushima S; Nomura H; Nojima S
    J Biochem; 1985 Jun; 97(6):1737-45. PubMed ID: 2993272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of specific antagonists on PAF-induced platelet aggregation and release of plasminogen activator.
    Hofmann B; Ostermann G; Hoffmann A; Klöcking HP; Kertscher HP
    Biomed Biochim Acta; 1988; 47(10-11):S157-60. PubMed ID: 3248103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PAF-like activity of O-acetylated sphingomyelin.
    Berdyshev EV; Getmanova OE
    Biomed Sci; 1991; 2(5):485-8. PubMed ID: 1840837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet-activating factor increases prostaglandin E(2) release from astrocyte-enriched cortical cell cultures.
    Teather LA; Lee RK; Wurtman RJ
    Brain Res; 2002 Aug; 946(1):87-95. PubMed ID: 12133598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.